ABS
4.11.2021 10:02:08 CET | Business Wire | Press release
At COP26, ABS, Hyundai Heavy Industries (HHI) and Korea Shipbuilding and Offshore Engineering (KSOE) have announced two landmark joint development projects (JDPs) to develop decarbonization technologies to support global sustainability ambitions.
The JDPs address green hydrogen production and offshore carbon capture and storage (CCS), two technologies which will be critical to achieving net zero.
ABS, HHI and KSOE will jointly develop technical guidance for green hydrogen production from offshore platforms as a key first step to the design and construction of a facility by 2025. The guidance will facilitate the development of production facilities providing a vital contribution in the growth of a global green hydrogen economy.
The project will utilize the electrolysis of seawater to generate green hydrogen. Later stages potentially include ABS Approval in Principle (AIP) and generic design approval, supporting engineering development right through to project construction.
A second offshore carbon capture JDP is focused on securing an AIP for HHI and KSOE’s design for a CO2 injection platform for offshore storage. The platform is designed to be able to store 400,000 tons of captured and liquefied CO2 every year from 2025.
The announcement is timed to coincide with the 2021 United Nations Climate Change Conference, COP26, in Glasgow, where the potential of green hydrogen to support global sustainability ambitions and the capture, utilization and sequestration of carbon will be central to the discussion. Green hydrogen is a fuel created using entirely renewable energy sources. Currently, only one percent of hydrogen fuel is produced this way.
“We are pleased to leverage our expertise in the green hydrogen and CCS platform pathway for decarbonization offshore. These projects are part of our continuous endeavors and commitment to a sustainable future that is aligned with HHI Group’s ESG vision, “Beyond Blue Forward to Green”. We also promise that HHI Group will encourage new value creation to lead the market, satisfying customers’ desire for the achievement of GHG zero emissions,” said Won Ho JOO, HHI Senior Executive Vice President and Chief Technical Officer.
“It is a quite meaningful technological milestone in obtaining the JDPs for these innovative green hydrogen and CCS platforms in offshore. KSOE believes our self-developed model will contribute to the global decarbonization effort. Also, we are preparing the development of the whole value chains of both CO2 and green hydrogen. In the near future, we will show the Perfect Net Zero technology,” said Sung Joon KIM, CTO of KSOE.
“Securing the required quantities of zero-carbon fuels to power our industry’s transition will require significant scaling up of the global renewable energy sources. Green hydrogen will certainly have a critical role to play but we are starting from a very low base and increasing production is an urgent global priority. Meanwhile, carbon capture is a potential game changer, and ABS is working to accelerate development of both the technology and the vessels required to make it viable,” said ABS Chairman, President and CEO, Christopher J. Wiernicki. “We are proud to be able to use our industry-leading offshore and sustainability expertise to support advances in these key areas of technology and the international decarbonization drive.”
▬▬
About ABS
ABS, a leading global provider of classification and technical advisory services to the marine and offshore industries, is committed to setting standards for safety and excellence in design and construction. Focused on safe and practical application of advanced technologies and digital solutions, ABS works with industry and clients to develop accurate and cost-effective compliance, optimized performance and operational efficiency for marine and offshore assets.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211104005089/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
